Advances in the treatment of atrophic age-related macular degeneration
10.3760/cma.j.cn511434-20240717-00273
- VernacularTitle:萎缩型年龄相关性黄斑变性治疗的研究进展
- Author:
Yang LIU
1
;
Junwen WANG
;
Yin LI
;
Tuo LI
Author Information
1. 湖北医药学院研究生院, 十堰 442000
- Publication Type:Journal Article
- Keywords:
Age-related macular degeneration;
Atrophic age-related macular degeneration;
Drusen;
Treatment;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2024;40(12):969-974
- CountryChina
- Language:Chinese
-
Abstract:
Age-related macular degeneration (AMD) is one of the leading causes of irreversible vision loss. There are two primary forms of AMD: exudative age-related macular degeneration (WAMD) and atrophic AMD (DAMD). While numerous medications are currently available for the treatment of WAMD, yielding significant therapeutic outcomes, effective treatments for DAMD remain scarce. Various animal studies and clinical trials on DAMD treatment have been conducted, focusing primarily on antioxidants, complement pathway inhibitors, mitochondrial protectors, visual cycle inhibitors, neuroprotectants, amphiphilic polymer-based drug delivery systems, cell therapy, photobiomodulation therapy, gene therapy, surgical interventions, and traditional Chinese medicine. Among these, antioxidant supplementation with vitamins and complement pathway inhibitor APL-2 and ACP have received Food and Drug Administration approval for the treatment of DAMD. With the continuous development of the medical field, the future will explore the treatment methods with little trauma, good efficacy and good patient compliance, and successfully achieve clinical transformation.
